Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 10, 2004, Pages 1131-1134

  Nuermberger, Eric L ^a   Yoshimatsu, Tetsuyuki ^a   Tyagi, Sandeep ^a   Williams, Kathy ^a   Rosenthal, Ian ^a   O'Brien, Richard J ^a   Vernon, Andrew A ^a   Chaisson, Richard E ^a   Bishai, William R ^a   Grosset, Jacques H ^a  

^a NONE

Author keywords

Fluoroquinolone; Mouse; Moxifloxacin; Pyrazinamide; Tuberculosis

Indexed keywords

ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DRUG EFFICACY; FEMALE; LONG TERM CARE; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SHORT COURSE THERAPY; SPLEEN WEIGHT; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MULTIVARIATE ANALYSIS; QUINOLINES; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, PULMONARY;

EID: 8444223157     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200407-885OC     Document Type: Article

References (21)

1. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-395.
2. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-2069.
3. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 2003;47:783-785.
4. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-89.
5. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002;46:1875-1879.
6. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-1345.
7. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-782.
8. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-426.
9. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis: second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982;126:460-462.
10. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991;143:700-706.
11. Singapore Tuberculosis Service/British Medical Research Council. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:779-783.
12. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 1981;62:95-102.
13. Jacobs WR Jr, Barletta RG, Udani R, Chan J, Kalkut G, Sosne G, Kieser T, Sarkis GJ, Hatfull GF, Bloom BR. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993;260:819-822.
14. Canetti G. The tubercle bacillus in the pulmonary lesions of man. New York: Springer Publishing Co.; 1955.
15. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In Gangadharam PRJ, Jenkins PA, editors. Mycobacteria, II chemotherapy. New York: Chapman & Hall; 1998. p. 51-97.
16. Nuermberger E, Yoshimatsu T, Tyagi S, Bishai WR, Grosset J. Assessment of moxifloxacin activity at clinically relevant dosages in the mouse model of tuberculosis [abstract]. Am J Respir Crit Care Med 2003;167:A433.
17. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985;132:374-378.
18. Singapore Tuberculosis Service/British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988;137:1147-1150.
19. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991;143:707-712.
20. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
21. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001;163:1055-1058.